<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chemoprevention of lung cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chemoprevention of lung cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chemoprevention of lung cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Keith, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            York E Miller, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rogerio C Lilenbaum, MD, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David E Midthun, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H200376535">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lung cancer is the leading cause of cancer deaths worldwide, with an estimated 2 million new cases and over 1.8 million deaths in 2018 [
         <a href="#rid1">
          1
         </a>
         ]. Tobacco smoking is responsible for most cases of lung cancer (approximately 90 percent for men and 70 to 85 percent for women). The risk of lung cancer with chronic marijuana smoking and use of electronic nicotine delivery devices remains to be determined. (See
         <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">
          "Cigarette smoking and other possible risk factors for lung cancer"
         </a>
         .)
        </p>
        <p>
         Never smoking or smoking cessation for smokers are the only proven means to decrease the risk of developing lung cancer. Former smokers continue to have an elevated risk of developing lung cancer for at least 30 years after stopping smoking, making these individuals an important target group for further efforts at mortality reduction [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">
          "Screening for lung cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">
          "Benefits and consequences of smoking cessation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">
          "Pharmacotherapy for smoking cessation in adults"
         </a>
         .)
        </p>
        <p>
         Chemoprevention is the use of dietary or pharmacologic agents to prevent or slow the progression of cancer [
         <a href="#rid4">
          4
         </a>
         ]. However, there is no convincing evidence that any approach other than smoking cessation can decrease the risk of lung cancer.
        </p>
        <p>
         Multiple agents have been studied to decrease the incidence of lung cancer, particularly in those at high risk for the development of this disease. The rationale for various approaches to chemoprevention (beyond never smoking or smoking cessation), observational data and their implications for epidemiologic studies, and results of chemoprevention trials that have been conducted are discussed in this topic.
        </p>
        <p class="headingAnchor" id="H200376548">
         <span class="h1">
          IDENTIFYING PATIENTS AT HIGH RISK FOR LUNG CANCER
         </span>
         <span class="headingEndMark">
          —
         </span>
         For chemoprevention to be feasible, a high-risk population must be identified and an effective chemopreventive agent with minimal side effects must be available. Current or former smokers with an annual risk of up to 2 percent are identifiable using a combination of clinically available risk factors, including: smoking history, age, sex, presence of airflow obstruction or emphysema, environmental/occupational exposure, a history of a tobacco-related aerodigestive cancer, and family history of lung cancer [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         The role of radiographic screening for lung cancer in patients at high risk is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">
          "Screening for lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H200376554">
         <span class="h1">
          IS THERE A TARGETABLE GENETIC LESION?
         </span>
         <span class="headingEndMark">
          —
         </span>
         All of the histologic cell types of lung cancer are genetically complex, with squamous cell demonstrating the highest frequency of mutations [
         <a href="#rid7">
          7
         </a>
         ]. No common mutation is shared across a majority of lung cancers, making a targeted approach to chemoprevention challenging. However, common pathways for the early stages of premalignancy (pulmonary inflammation, tissue hypoxia, aging) or distinct phenotypes susceptible to lung carcinogenesis may be definable and targeted for intervention [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2510475269">
         <span class="h2">
          Process of carcinogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carcinogenesis in the lung proceeds through a multistep process [
         <a href="#rid11">
          11
         </a>
         ]. The airways of smokers are directly exposed to a complex mixture of carcinogens in tobacco smoke, which can result in a field effect with multiple premalignant clonal lesions [
         <a href="#rid12">
          12,13
         </a>
         ]. Invasive tumors are often surrounded by an area of relatively normal epithelium harboring some of the same mutations that are found in the carcinoma, supporting the multistep carcinogenesis hypothesis [
         <a href="#rid14">
          14
         </a>
         ]. Whole-genome sequencing of cultured clones arising from single bronchial epithelial cells from a series of 16 individuals of differing age and smoking history has revealed that tobacco smoking has a massive effect on the mutational burden of these cells, with 1000 to 10,000 mutations per cell in current smokers [
         <a href="#rid15">
          15
         </a>
         ]. In former smokers, a population of bronchial epithelial cells with a much lower mutational burden emerged, demonstrating expansion of a population of mitotically quiescent progenitor cells that could presumably repair tobacco-damaged epithelium.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A central airway progression of premalignant lesions (squamous metaplasia; mild, moderate, and severe dysplasia; and carcinoma in situ) has been described, which leads to invasive squamous cell carcinoma [
         <a href="#rid16">
          16
         </a>
         ]. A subset of these premalignant lesions exhibits gene copy number alterations and is associated with increased squamous cell lung cancer risk [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These premalignant lesions may be sampled either by routine white light or autofluorescence bronchoscopy [
         <a href="#rid19">
          19
         </a>
         ]. Histologic changes at a single timepoint, with the possible exception of carcinoma in situ, are not highly predictive of the future development of invasive squamous cell lung cancer [
         <a href="#rid20">
          20
         </a>
         ]. The evolution of a dysplastic lesion, regression or persistence and progression, is significantly associated with risk of incident squamous cell lung cancer, although these often arise at a site distinct from the persistent/progressive lesion [
         <a href="#rid21">
          21
         </a>
         ]. Carcinoma in situ is also often identified adjacent to invasive squamous cell carcinoma. The finding of carcinoma in situ in the absence of carcinoma should usually prompt a careful evaluation, including computed tomography (CT) and repeat bronchoscopy with multiple biopsies, to determine if an occult invasive lesion is present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A comprehensive genomic, epigenomic, and transcriptomic analysis of carcinoma in situ lesions that have either progressed to invasive squamous cell carcinoma or regressed has yielded important insights into mechanisms driving progression [
         <a href="#rid22">
          22
         </a>
         ]. One consistent signal for progression is expression of genes associated with chromosomal instability, including expression of the genes
         <em>
          ACTL6A, ELAVL1, MAD2L1, NEK2,
         </em>
         and
         <em>
          OIP5.
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The immune microenvironment is associated with progression or regression of squamous cell premalignancy, supporting the concept that regression is often an immune-mediated process [
         <a href="#rid23">
          23-25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An analogous, but histologically distinct, series of premalignant lesions, including atypical adenomatous hyperplasia and adenocarcinoma in situ, occurs in the peripheral lung; these lesions can progress to invasive adenocarcinoma [
         <a href="#rid26">
          26
         </a>
         ]. Many of these lesions are initially detected on low-dose chest CT scans performed for lung cancer screening, or they are incidentally noted on chest CT scans done for other clinical indications. (See
         <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">
          "Pathology of lung malignancies", section on '2021 classification of adenocarcinoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The understanding of premalignant genetic alterations in peripheral lung lesions that give rise to adenocarcinoma has been hampered by difficulty in obtaining biospecimens other than in surgical resections, although new bronchoscopic techniques may alleviate this partially. Serial sampling of peripheral premalignancy to understand mechanisms of regression remains in its infancy. Premalignant lesions separate from a resected adenocarcinoma have undergone genomic investigation [
         <a href="#rid27">
          27
         </a>
         ]. Kirsten rat sarcoma viral oncogene homolog (
         <em>
          KRAS
         </em>
         ) mutations were identified in a minority (18 percent) of smoking-associated lesions, but were not seen in lesions arising in never-smokers. B-Raf proto-oncogene (
         <em>
          BRAF
         </em>
         ) mutations were discovered in 23 percent of patients, both in ever- and never-smokers. Gene set expression analysis supported the hypothesis that antitumor immune signaling is suppressed and protumor immune signaling is enhanced in atypical adenomatous hyperplasia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Peripheral premalignant lesions are often identifiable as small ground-glass infiltrates on CT scans, although ground-glass infiltrates are nonspecific and can arise from inflammation as well as premalignancy [
         <a href="#rid28">
          28
         </a>
         ]. With the widespread use of CT screening for lung cancer, more atypical adenomatous hyperplasia lesions will likely be identified. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs", section on 'Ground-glass opacification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Premalignant lesions for small cell lung cancer have not been described.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H200376566">
         <span class="h1">
          INVESTIGATIVE STRATEGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic and observational studies have established the importance of smoking cessation, but have not led to other effective lung cancer prevention strategies. The health effects of smoking cessation are addressed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">
          "Benefits and consequences of smoking cessation", section on 'Malignancy'
         </a>
         .)
        </p>
        <p>
         Data regarding three agents (inhaled corticosteroids, low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , anti-interleukin 1 beta [IL-1 beta] monoclonal antibodies) have attracted interest as possible agents for lung cancer chemoprevention. However, multiple phase III lung cancer chemoprevention trials have failed to establish the efficacy of a variety of approaches, which emphasizes the fact that current approaches to predict efficacy are inadequate [
         <a href="#rid29">
          29
         </a>
         ]. We suggest not using these agents for chemoprevention against lung cancer, given that further evaluation in randomized trials is required.
        </p>
        <p>
         Epidemiologic studies have also identified a number of factors that appear to be related to a decreased incidence of lung cancer. However, it is likely that many of these associations are confounded by covarying factors, such as socioeconomic status, education, and smoking.
        </p>
        <p class="headingAnchor" id="H200376573">
         <span class="h2">
          Clinical settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemoprevention is classified as primary, secondary, or tertiary, based upon the target population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary chemoprevention – Primary chemoprevention refers to preventing cancer in healthy individuals who are at increased risk. This population primarily includes current and former smokers, as well as those with exposure to known lung carcinogens such as asbestos and radon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary chemoprevention – Secondary chemoprevention focuses on blocking the development of cancer in individuals in whom a precancerous lesion has been detected. (See
         <a class="local">
          'Is there a targetable genetic lesion?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tertiary chemoprevention – Tertiary chemoprevention targets patients who had a previous lung or other tobacco-related cancer in an effort to prevent the development of a second primary tumor.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H200376579">
         <span class="h2">
          Primary prevention
         </span>
        </p>
        <p class="headingAnchor" id="H358628804">
         <span class="h3">
          Aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         has demonstrated a protective benefit on lung cancer deaths in a randomized trial, it remains unclear whether this is from suppression of metastases in patients who already have lung cancer versus reduced incidence of new cancers. Observational data support a chemopreventive role for aspirin. Further randomized trial data are needed before using aspirin for lung cancer prevention.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         has been extensively studied for the prevention of cardiovascular disease. Pooled data from seven such trials in which multiple individual patient outcomes were available have been correlated with both cancer deaths and cancer metastasis [
         <a href="#rid30">
          30
         </a>
         ]. The analysis included 23,535 patients with 657 cancer deaths, of which 198 were from lung cancer. Benefit in cancer deaths was only seen after five years' or more follow-up; deaths from lung cancer showed a consistent reduced hazard ratio (HR) across various time periods ranging from 0.68 to 0.75, with statistically significant values at 0 to 10 years and 0 to 20 years' follow-up. The potential benefit was only observed for adenocarcinoma, not other cell types. A further analysis of this study showed similar reductions in lung cancer metastasis, suggesting that at least some of the effect may have been due to suppression of metastasis, rather than interference in earlier stages of carcinogenesis [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, in a retrospective cohort study of almost 13 million participants in the Korean National Health Information Database, intake of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (100 mg or less) for at least five years was associated with a modestly reduced risk of lung cancer (eg, compared with no aspirin use; HR 0.96 with five to six years of aspirin use and reaching 0.89 with nine years of aspirin use) [
         <a href="#rid32">
          32
         </a>
         ]. After stratified analysis, a more pronounced reduction of lung cancer risk was observed among people aged 65 years or older and among people without diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Results from the Women's Health Study also support to a possible chemopreventive activity of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for lung cancer. In the Women's Health Study, a 2 x 2 design study of low-dose aspirin and
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         , newly diagnosed invasive cancer was the primary endpoint, with incident breast, colorectal, and lung cancer as predetermined secondary endpoints [
         <a href="#rid33">
          33
         </a>
         ]. No effect of aspirin on total incident cancer or incident breast or colorectal cancer was found, with or without vitamin E. However, a trend toward a decreased incidence of lung cancer was noted (relative risk [RR] 0.78, 95% CI 0.59-1.03), and there was a statistically significant decrease in lung cancer mortality (RR 0.7, 95% CI 0.50-0.99; p = 0.04). Although encouraging, these results must be tempered by consideration of multiple endpoint testing and a potential effect on lung cancer death through suppression of metastasis rather than incidence.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2169442954">
         <span class="h3">
          Vitamins and minerals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diets high in fruit and vegetables have been consistently associated with reduced lung cancer risk [
         <a href="#rid34">
          34
         </a>
         ]. However, no positive trials of dietary intervention to decrease the risk of lung cancer have been reported. Reduced serum levels of antioxidants and vitamins, particularly
         <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">
          vitamin A
         </a>
         , have been reported in patients with lung cancer, further supporting the concept that supplementation might be protective. Unfortunately, randomized trials of chemoprevention with vitamins and antioxidants have shown no benefits in regards to reduced lung cancer, and these strategies are not used as chemoprevention.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          Vitamin E
         </a>
         and beta carotene – Three primary chemoprevention trials have evaluated: the combination of vitamin E and beta carotene (the alpha tocopherol beta carotene or ATBC study), beta carotene and retinol (CARET), or beta carotene alone [
         <a href="#rid35">
          35-37
         </a>
         ]. None showed benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In regards to beta carotene, both CARET and ATBC demonstrated statistically significant increases (RR 1.28 and 1.18, respectively) in lung cancer risk in the treatment groups with this vitamin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In regards to
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         , a benefit was not observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A combination of multivitamins and minerals was ineffective in a large primary prevention trial [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2067760326">
         <span class="h3">
          Inhaled corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary inflammation induced by tobacco smoke may contribute to the development of lung cancer, but further data are required before inhaled corticosteroids can be supported as a chemoprevention strategy for lung cancer.
        </p>
        <p>
         The effect of inhaled corticosteroids on the natural history of chronic obstructive pulmonary disease has been studied in several double-blinded, randomized trials. Although no reduction in lung cancer incidence was observed, the mean duration of these trials was only 26 months, which may have been too short to demonstrate a chemopreventive effect.
        </p>
        <p>
         By contrast, an analysis of patients at Veterans Affairs Medical Centers who were prescribed inhaled corticosteroids for chronic obstructive pulmonary disease and were highly compliant revealed a significantly reduced risk of lung cancer [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1516883605">
         <span class="h3">
          Canakinumab (IL-1 beta inhibitor)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The monoclonal antibody
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         targets interleukin 1 beta (IL-1 beta) and is an investigative option, being evaluated for several conditions, but is not used for lung cancer prevention outside of a clinical trial.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          Canakinumab
         </a>
         was studied in a randomized, placebo-controlled trial with the primary endpoint of reducing vascular events in patients with a previous myocardial infarction and an elevated level of high-sensitivity C-reactive protein (2 mg/L or greater). Lung cancer incidence was a prespecified secondary endpoint and was reduced significantly in the canakinumab group in a dose-dependent fashion ranging from HRs of 0.61 to 0.33 over a median follow-up period of 3.7 years [
         <a href="#rid40">
          40
         </a>
         ]. The short follow-up period makes it unlikely that canakinumab inhibits early events in lung carcinogenesis, but more likely affects progression or metastasis. Overall mortality was not improved, largely due to an increase in death from sepsis. Canakinumab is being studied in many early-stage lung cancer treatment trials, and several of these trials are collecting second primary tumor data.
        </p>
        <p class="headingAnchor" id="H200376585">
         <span class="h2">
          Secondary chemoprevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Secondary chemoprevention refers to the prevention of progression to lung cancer for people who have evidence of premalignancy. Several agents, including oral
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         and
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         , have achieved promising results in phase II trials as secondary prevention, but the endpoints that were modulated have not been validated as predictive. As such, further data are required prior to use of these agents as secondary chemoprevention against lung cancer.
        </p>
        <p>
         Ideally, surrogate endpoints for lung cancer chemoprevention should be:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated with lung cancer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanistically involved in the carcinogenesis process
        </p>
        <p>
        </p>
        <p>
         However, studies to date have used surrogate endpoints including endobronchial dysplasia, bronchial epithelial proliferation as measured by Ki-67 immunostaining, and the presence of computed tomography (CT)-detected lung nodules. None of these endpoints have been validated as fulfilling the above criteria of an ideal surrogate endpoint and are justified on the basis of biologic plausibility.
        </p>
        <p>
         A number of studies have used bronchoscopy to target premalignant airway lesions but few of these have met their primary endpoints. Examples include the following [
         <a href="#rid41">
          41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative results have been reported for 13-cis retinoic acid [
         <a href="#rid42">
          42,43
         </a>
         ], fenretinide [
         <a href="#rid44">
          44
         </a>
         ], etretinate [
         <a href="#rid45">
          45
         </a>
         ], beta carotene [
         <a href="#rid46">
          46
         </a>
         ], vitamin B12 and folate [
         <a href="#rid47">
          47
         </a>
         ], and inhaled corticosteroids [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study of anethole dithiolethione, a compound found in green tea, did not achieve its primary endpoint of reducing new dysplastic lesions but did decrease the rate of worsening of endobronchial lesions, a secondary endpoint [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two trials of the COX-2 inhibitor
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         with bronchial epithelial proliferation as the primary endpoint have been positive [
         <a href="#rid51">
          51,52
         </a>
         ]. The biologic basis for COX-2 inhibition is attractive. COX-2 overexpression is seen in non-small cell lung cancer (NSCLC) and adenocarcinoma precursor lesions, and COX-2 inhibition inhibits chemical carcinogenesis in murine lung cancer models.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One trial of the oral prostacyclin analog
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         compared with placebo demonstrated a statistically significant improvement in the primary endpoint, bronchial dysplasia, but only in former smokers [
         <a href="#rid53">
          53
         </a>
         ]. The improvement in bronchial dysplasia was similar to the difference between current and former smokers. Oral iloprost is no longer available, but a phase I trial of inhaled iloprost has been completed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In preclinical models, prostacyclin and
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         do not act through the canonical cell surface prostacyclin receptor, but rather at least partially through peroxisomal proliferator-activated receptor (PPAR) gamma activation [
         <a href="#rid54">
          54
         </a>
         ]. A phase II trial of oral
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          pioglitazone
         </a>
         (a PPAR gamma activator) with the endpoint of bronchial dysplasia was completed and did not show evidence of efficacy [
         <a href="#rid55">
          55
         </a>
         ], suggesting that differences in the mechanisms of activity exist.
        </p>
        <p>
        </p>
        <p>
         Several trials have assessed innovative endpoints:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one trial of inhaled
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         with the primary endpoint of bronchial dysplasia, dysplasia did not improve, but a secondary endpoint, the proportion of CT-detected pulmonary nodules, did respond [
         <a href="#rid56">
          56
         </a>
         ]. Two subsequent phase II trials of inhaled corticosteroid with the primary endpoint of CT-detected pulmonary nodules were negative, however [
         <a href="#rid48">
          48,49
         </a>
         ]. Although CT-detected nodules (particularly ground-glass nodules) are a nonspecific endpoint, some do represent adenocarcinoma premalignancy, and further consideration of using this novel surrogate endpoint, perhaps with histologic confirmation, is warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gene expression analysis of endobronchial brushings has been carried out in a small phase I trial of myo-inositol, with the finding that activation of the phosphatidylinositol 3-kinase (PI3K) pathway was associated with response to myo-inositol, which has PI3K inhibitory effects [
         <a href="#rid57">
          57
         </a>
         ]. A follow-up phase II randomized placebo-controlled trial failed to demonstrate either efficacy of myo-inositol or activation of the PI3K pathway as a predictive biomarker [
         <a href="#rid58">
          58
         </a>
         ]. While disappointing, these two trials have raised enthusiasm for studying alterations in premalignancy and precision chemoprevention where agents target specific activated pathways [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Prevention trials have also started to evaluate modulation of the immune response. Immunoprevention trials evaluating checkpoint inhibitors are recruiting (
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         for premalignant squamous cell lesions [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03347838&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSz9wsRalc77CFv9OFo%2BGIinARzQ4aQLaF0jr7tCcNXgqg%3D%3D&amp;TOPIC_ID=4604" target="_blank">
          NCT03347838
         </a>
         ], and a trial of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in pulmonary nodules [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03634241&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSz9wsRalc77CFv9OFo%2BGIin8O0Q91wgymiaOVcBqewpPg%3D%3D&amp;TOPIC_ID=4604" target="_blank">
          NCT03634241
         </a>
         ]).
        </p>
        <p class="headingAnchor" id="H4254053457">
         <span class="h2">
          Tertiary prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         No interventions have reduced the occurrence of a second or recurrent lung cancer in patients previously diagnosed with lung cancer, with the exception of smoking cessation.
        </p>
        <p>
         In a 2010 meta-analysis of 10 observational studies including patients with early-stage lung cancer, continued smoking was associated with increased all-cause mortality (HR 2.9) and recurrence (HR 1.9) in early-stage NSCLC, and in all-cause mortality (HR 1.9), development of a secondary primary tumor (HR 4.3), and recurrence (HR 1.3) in limited small cell lung cancer [
         <a href="#rid60">
          60
         </a>
         ]. No study contained data on the effect of quitting smoking on cancer-specific mortality or the development of a second primary tumor in NSCLC.
        </p>
        <p>
         Subsequent studies have confirmed these findings [
         <a href="#rid61">
          61-63
         </a>
         ]. As an example, among over 7059 patients diagnosed with primary lung cancer, 2.3 percent developed a second primary lung cancer [
         <a href="#rid61">
          61
         </a>
         ]. Smoking cessation was associated with an 83 percent RR reduction for second primary lung cancer (HR 0.17).
        </p>
        <p>
         Further discussion on the health benefits of smoking cessation is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">
          "Benefits and consequences of smoking cessation", section on 'Malignancy'
         </a>
         .)
        </p>
        <p>
         Examples of available data regarding other interventions include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          Selenium
         </a>
         supplementation was associated with decreased incidence of lung cancer in a trial with skin cancer as the primary endpoint but was ineffective in a subsequent tertiary prevention trial with second primary lung cancer as the endpoint [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         13-cis retinoic acid and the combination of
         <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">
          vitamin A
         </a>
         and n-acetyl cysteine have been evaluated in two trials of patients with a history of cancer (tertiary chemoprevention), both of which showed no beneficial effect [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3416643280">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">
          "Society guideline links: Diagnosis and management of lung cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H200376604">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         – Never-smoking and smoking cessation among smokers clearly reduce the risk of lung cancer, and the leading prevention effort for current smokers should be smoking cessation. Chemoprevention is the use of dietary or pharmacologic agents to prevent or slow the progression of cancer [
         <a href="#rid4">
          4
         </a>
         ]. However, there is no convincing evidence that any approach other than smoking cessation can decrease the risk of lung cancer. (See
         <a class="local">
          'Identifying patients at high risk for lung cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Investigative strategies
         </strong>
         – Although lung cancer chemoprevention has considerable potential, the strategies discussed below are investigational and we do not use them for lung cancer chemoprevention.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary prevention
         </strong>
         – Primary chemoprevention refers to preventing cancer in healthy individuals who are at increased risk. This population primarily includes current and former smokers, as well as those with exposure to known lung carcinogens.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Efforts to prevent lung cancer have included a variety of agents, including
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , beta carotene, multivitamins, and the interleukin 1 beta inhibitor
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         . None have been successful in phase III trials, and beta carotene supplementation actually increases lung cancer risk, emphasizing that the administration of supplements with a good biologic rationale to reduce risk is not necessarily benign. (See
         <a class="local">
          'Investigative strategies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Secondary prevention
         </strong>
         – Secondary chemoprevention focuses on blocking the development of cancer in individuals in whom a precancerous lesion has been detected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Several agents, including oral
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         and
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         , have achieved promising results in phase II trials, but the endpoints that were modulated have not been validated as predictive.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tertiary prevention
         </strong>
         – No interventions have reduced the occurrence of a second or recurrent lung cancer in patients previously diagnosed with lung cancer, with the possible exception of smoking cessation.
         <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">
          Selenium
         </a>
         supplementation was associated with decreased incidence of lung cancer in a trial with skin cancer as the primary endpoint but was ineffective in a subsequent tertiary prevention trial with second primary lung cancer as the endpoint.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H265564390">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Arthur Skarin, MD and Ravi Salgia, MD, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          The Global Cancer Observatory. International Agency for Research on Cancer. World fact sheets. http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on February 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36:2699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003; 12:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008; 178:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghaddam SJ, Li H, Cho SN, et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 2009; 40:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karoor V, Le M, Merrick D, et al. Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer Prev Res (Phila) 2012; 5:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol 2006; 1:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakubek Y, Lang W, Vattathil S, et al. Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Res 2016; 76:3676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida K, Gowers KHC, Lee-Six H, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 2020; 578:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson AG, Perry LJ, Cury PM, et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation. Histopathology 2001; 38:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonsson S, Varella-Garcia M, Miller YE, et al. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am J Respir Crit Care Med 2008; 177:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Boerdonk RA, Sutedja TG, Snijders PJ, et al. DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. Am J Respir Crit Care Med 2011; 184:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 93:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee AK. Preinvasive lesions of the bronchus. J Thorac Oncol 2009; 4:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrick DT, Gao D, Miller YE, et al. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila) 2016; 9:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teixeira VH, Pipinikas CP, Pennycuick A, et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat Med 2019; 25:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrick DT, Edwards MG, Franklin WA, et al. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 2018; 78:4971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beane JE, Mazzilli SA, Campbell JD, et al. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat Commun 2019; 10:1856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mascaux C, Angelova M, Vasaturo A, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 2019; 571:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivakumar S, San Lucas FA, McDowell TL, et al. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res 2017; 77:6119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Austin JH, Garg K, Aberle D, et al. Radiologic implications of the 2011 classification of adenocarcinoma of the lung. Radiology 2013; 266:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly RJ, Lopez-Chavez A, Szabo E. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Curr Drug Targets 2011; 12:1983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ye S, Lee M, Lee D, et al. Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer. JAMA Netw Open 2019; 2:e190185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito Y, Wakai K, Suzuki K, et al. Lung cancer mortality and serum levels of carotenoids, retinol, tocopherols, and folic acid in men and women: a case-control study nested in the JACC Study. J Epidemiol 2005; 15:S140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omenn GS, Goodman G, Thornquist M, et al. Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers. IARC Sci Publ 1996; :67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamangar F, Qiao YL, Yu B, et al. Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 2006; 15:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 2013; 10:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly K, Kittelson J, Franklin WA, et al. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila) 2009; 2:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6:2973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992; 65:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLarty JW, Holiday DB, Girard WM, et al. Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995; 62:1431S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heimburger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 1988; 259:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Berg RM, Teertstra HJ, van Zandwijk N, et al. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer 2008; 60:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veronesi G, Szabo E, Decensi A, et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) 2011; 4:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim ES, Hong WK, Lee JJ, et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 2010; 3:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mao JT, Roth MD, Fishbein MC, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 2011; 4:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keith RL, Blatchford PJ, Kittelson J, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011; 4:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemenoff R, Meyer AM, Hudish TM, et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila) 2008; 1:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keith RL, Blatchford PJ, Merrick DT, et al. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers. Cancer Prev Res (Phila) 2019; 12:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004; 10:6502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gustafson AM, Soldi R, Anderlind C, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010; 2:26ra25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam S, Mandrekar SJ, Gesthalter Y, et al. A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia. Cancer Prev Res (Phila) 2016; 9:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kensler TW, Spira A, Garber JE, et al. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) 2016; 9:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340:b5569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aredo JV, Luo SJ, Gardner RM, et al. Tobacco Smoking and Risk of Second Primary Lung Cancer. J Thorac Oncol 2021; 16:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh M, Mukeriya A, Shangina O, et al. Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality : A Prospective Cohort Study. Ann Intern Med 2021; 174:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiden BT, Eaton DB Jr, Chang SH, et al. The Impact of Persistent Smoking After Surgery on Long-term Outcomes After Stage I Non-small Cell Lung Cancer Resection. Chest 2022; 161:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karp DD, Lee SJ, Keller SM, et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 2013; 31:4179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4604 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Global Cancer Observatory. International Agency for Research on Cancer. World fact sheets. http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on February 18, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8445673" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Patterns of absolute risk of lung cancer mortality in former smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15710956" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1277177" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Approaches to prevention of epithelial cancer during the preneoplastic period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14578133" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470739" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A risk model for prediction of lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22960745" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Comprehensive genomic characterization of squamous cell lung cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565949" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Association of radiographic emphysema and airflow obstruction with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18927348" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22700853" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039118" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lung cancer preneoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13094644" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702551" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27216194" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31996850" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Tobacco smoking and somatic mutations in human bronchial epithelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11260299" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17989344" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21799074" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11562389" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19279508" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Preinvasive lesions of the bronchus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26542061" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30664780" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29997230" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31015447" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31243362" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Immune evasion before tumour invasion in early lung squamous carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21252716" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28951454" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23070271" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Radiologic implications of the 2011 classification of adenocarcinoma of the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21158704" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21144578" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22440947" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30821825" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15998890" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16127226" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lung cancer mortality and serum levels of carotenoids, retinol, tocopherols, and folic acid in men and women: a case-control study nested in the JACC Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8791118" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8127329" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8602179" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896051" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185647" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28855077" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of interleukin-1βinhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689750" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Lung cancer chemoprevention: current status and future prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19401528" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8164045" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10955773" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1586601" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7495244" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3339790" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17983686" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21163939" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12096085" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20103722" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21733822" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lung cancer chemoprevention with celecoxib in former smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21636546" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Oral iloprost improves endobronchial dysplasia in former smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19138979" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31308004" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15475437" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20375364" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Airway PI3K pathway activation is an early and reversible event in lung cancer development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27658890" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26744449" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20093278" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33722709" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Tobacco Smoking and Risk of Second Primary Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34310171" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality : A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34919892" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The Impact of Persistent Smoking After Surgery on Long-term Outcomes After Stage I Non-small Cell Lung Cancer Resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002495" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10861309" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11309437" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
